List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) - Overview
Premature Labor (Tocolysis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Dare Bioscience Inc
GlaxoSmithKline Plc
ObsEva SA
Premature Labor (Tocolysis) - Drug Profiles
OBE-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Premature Labor (Tocolysis), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Premature Labor (Tocolysis) - Pipeline by Dare Bioscience Inc, H2 2019
Table 11: Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 12: Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2019
Table 13: Premature Labor (Tocolysis) - Dormant Projects, H2 2019
Table 14: Premature Labor (Tocolysis) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Premature Labor (Tocolysis), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Dare Bioscience Inc
• GlaxoSmithKline Plc
• ObsEva SA